Financial analysts update price targets for several major companies

Several companies have seen adjustments to their stock price targets and analyst ratings following recent research reports.

Citigroup lowered its price target for Olema Pharmaceuticals to $59.00 while maintaining a “buy” rating. Other firms, including HC Wainwright and Guggenheim, have also issued updated targets for the company.

Affirm received a price target increase from BMO Capital Markets, raising it from $78.00 to $86.00 with an “outperform” rating. This follows previous adjustments from Robert W. Baird and Deutsche Bank.

Karman saw its price objective increased by Citigroup from $76.00 to $78.00, maintaining a “buy” rating. Other analysts, such as those from Royal Bank of Canada and Piper Sandler, have also recently updated their outlooks for the firm.

Aramark’s target price was raised by Robert W. Baird from $63.00 to $69.00 with an “outperform” rating. Citigroup and JPMorgan Chase & Co. have also previously issued positive price targets for the company.